Postprandial ultra-fast insulin versus mealtime fast-acting insulin in adults with cystic fibrosis-related diabetes: A randomized multicentre crossover trial
Primary result · TIR (70-180 mg/dL)Result — go to the resultEstimated difference + 1.1 percentage points 95% CI −1.1 to + 3.3Authors' conclusion
These findings support the potential of postprandial ultra-fast-acting insulin as a flexible treatment option for adults with CFRD.
Study context
- Population
- Adults with cystic fibrosis-related diabetes; mean age 33 ± 11 years; 56% receiving CFTR modulators34 in ITT analysis
- Participants
- 38 adults
- Comparison
- Postprandial ultra-fast-acting insulin vs mealtime fast-acting insulin
- Primary endpoint
- TIR (70-180 mg/dL)
Methodological detailsopen-label, multicentre, phase IV, crossover, two-sequence, four-period design
- Open-label
- Multicentre
- Phase IV
- Crossover
- Two-sequence, four-period design
Primary result
As reported in the abstract
Estimated difference
+ 1.1 percentage points
95% CI −1.1 to + 3.3
P = 0.316
Further findings
Baseline glycaemia and lung function
- Baseline TIR
- 74% [68-83]
- Baseline time below range (<70 mg/dL)
- 4.1% [1.9-6.7]
- Baseline ppFEV1
- 71 ± 25%
Other CGM metrics, HbA1c and insulin doses
- Other CGM metrics, HbA1c and insulin doses were comparable between treatments
Original publication
Postprandial ultra-fast insulin versus mealtime fast-acting insulin in adults with cystic fibrosis-related diabetes: A randomized multicentre crossover trial. Diabetes Res Clin Pract. Published 1 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →